PPD (PPDI) Confirms Takeda Receives FDA Complete Response for Alogliptin
More News related to PPDI
- PPD to Present at CHINATRIALS 2009
- PPD Completes Acquisition of Excel PharmaStudies
- Wells Fargo Downgrades Pharmaceutical Product Development (PPDI) from Outperform
- PPD (PPDI) Awarded $2.7M Contract by US FDA to Evaluate Spontaneous Adverse Event Reports
- Pharmaceutical Product Development (PPDI) Reports Inline Q3 EPS of $0.32
PPD, Inc. (NASDAQ: PPDI) announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin.
PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.19Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
